Neurocrine Biosciences (NBIX): Buy Ahead Of valbenazine Tourette’s Data - BMO
Tweet Send to a Friend
BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Neurocrine Bio. (NASDAQ: NBIX) seeing the recent price weakness as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE